<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6893414\results\search\disease\results.xml">
  <result pre="VirusesVirusesvirusesViruses1999-4915MDPI doi: 10.3390/v11111064viruses-11-01064 : Article Erythromycin Estolate Inhibits Zika Virus" exact="Infection" post="by Blocking Viral Entry as a Viral Inactivator WangXiaohuanhttps://orcid.org/0000-0001-7896-4182XiaShuaiZouPeng*https://orcid.org/0000-0002-2255-0391LuLu*[],"/>
  <result pre=": Article Erythromycin Estolate Inhibits Zika Virus Infection by Blocking" exact="Viral" post="Entry as a Viral Inactivator WangXiaohuanhttps://orcid.org/0000-0001-7896-4182XiaShuaiZouPeng*https://orcid.org/0000-0002-2255-0391LuLu*[], 18111010062@fudan.edu.cn15111010053@fudan.edu.cn *Correspondence: zoupeng@shphc.org.cn"/>
  <result pre="Inhibits Zika Virus Infection by Blocking Viral Entry as a" exact="Viral" post="Inactivator WangXiaohuanhttps://orcid.org/0000-0001-7896-4182XiaShuaiZouPeng*https://orcid.org/0000-0002-2255-0391LuLu*[], 18111010062@fudan.edu.cn15111010053@fudan.edu.cn *Correspondence: zoupeng@shphc.org.cn (P.Z.); lul@fudan.edu.cn (L.L.); Tel.:"/>
  <result pre="of the macrolide antibiotics, was found to effectively inhibit ZIKV" exact="infection" post="in different cell types and significantly protect A129 mice"/>
  <result pre="to inhibit ZIKV entry by disrupting the integrity of the" exact="viral" post="membrane which resulted in the loss of ZIKV infectivity."/>
  <result pre="Ery-Est also showed inhibitory activity against dengue virus (DENV) and" exact="yellow fever" post="virus (YFV). Thus, Ery-Est may be a promising drug"/>
  <result pre="patients with ZIKV infection, particularly pregnant women. erythromycin estolate ZIKV" exact="viral" post="entry inhibitor inactivator 1. Introduction Zika virus (ZIKV), a"/>
  <result pre="also contains other enveloped viruses, such as dengue virus (DENV)," exact="yellow fever" post="virus (YFV), West Nile virus, and Japanese encephalitis virus,"/>
  <result pre="virus (DENV), yellow fever virus (YFV), West Nile virus, and" exact="Japanese encephalitis" post="virus, which have resulted in epidemics and threatened public"/>
  <result pre="(DENV), yellow fever virus (YFV), West Nile virus, and Japanese" exact="encephalitis" post="virus, which have resulted in epidemics and threatened public"/>
  <result pre="and received attention globally. More recently, unexpected outbreaks of ZIKV" exact="infection" post="have occurred in Brazil and rapidly spread from South"/>
  <result pre="(WHO) [6]. ZIKV was found to be associated with Guillainâ€&quot;BarrÃ©" exact="syndrome" post="in the epidemics of French Polynesia, and further damage"/>
  <result pre="French Polynesia, and further damage caused by ZIKV, including severe" exact="congenital" post="malformation, optic nerve abnormality, and reproductive system injury, have"/>
  <result pre="further damage caused by ZIKV, including severe congenital malformation, optic" exact="nerve" post="abnormality, and reproductive system injury, have been discovered in"/>
  <result pre="ZIKV, is a fetal neurodevelopmental defect with resulting physical and" exact="learning disabilities," post="greatly impacting the quality of life of affected children"/>
  <result pre="roles in suppressing the virusâ€&quot;host interaction and membrane fusion, restraining" exact="viral" post="replication and translation, or disturbing autophagy, have been explored"/>
  <result pre="safely used by pregnant women, was found to inhibit ZIKV" exact="infection" post="efficiently. Ery-Est, one of the macrolide antibiotics, is the"/>
  <result pre="(Figure 1A), and it has commonly been used for clinical" exact="bacterial infections." post="Besides, some macrolide antibiotics have been studied to treat"/>
  <result pre="clarithromycin and the macrolide therapy have been utilized to treat" exact="respiratory" post="syncytial virus and Middle East respiratory syndrome coronavirus (MERS-CoV)"/>
  <result pre="been utilized to treat respiratory syncytial virus and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) infection respectively, and ivermectin and azithromycin"/>
  <result pre="utilized to treat respiratory syncytial virus and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) infection respectively, and ivermectin and azithromycin (Azi)"/>
  <result pre="respiratory syncytial virus and Middle East respiratory syndrome coronavirus (MERS-CoV)" exact="infection" post="respectively, and ivermectin and azithromycin (Azi) were identified to"/>
  <result pre="ivermectin and azithromycin (Azi) were identified to effectively inhibit ZIKV" exact="infection" post="[17,18,19,20,21,22,23]. To the best of our knowledge, this is"/>
  <result pre="(DMSO) and then stored at âˆ’20 Â°C. 2.3. Plaque Assay" exact="Viral" post="titers were determined by plaque assay performed on BHK21"/>
  <result pre="at 37 Â°C for 12 h, followed by replacing the" exact="viral" post="supernatant with fresh DMEM containing 2% FBS. When the"/>
  <result pre="DMEM containing 1% LMP agarose and 2% FBS. When the" exact="viral" post="plaque became obvious, the plaque visualization was carried out"/>
  <result pre="To test the inhibitory activity of Ery-Est against ZIKV in" exact="neuronal" post="cells, U-251 MG cells were used. Briefly, Ery-Est and"/>
  <result pre="The inhibition of Ery-Est against ZIKV in multiple rounds of" exact="infection" post="was performed as previously described [29]. BHK21 cells (2"/>
  <result pre="Additionally, to test the inhibitory activity of Ery-Est against high" exact="viral" post="doses of ZIKV, the experiment was performed with a"/>
  <result pre="of ZIKV, the experiment was performed with a multiplicity of" exact="infection" post="(MOI) of 0.1 as previously described [30]. Briefly, BHK21"/>
  <result pre="detected by the plaque assay. The pseudotyped MERS-CoV and vesicular" exact="stomatitis" post="virus (VSV) were chosen as control enveloped viruses and"/>
  <result pre="the coverslips were sealed with Prolong Gold Antifade reagent (Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) and scanned with a Leica"/>
  <result pre="with ZIKV at 4 Â°C for 1 h to allow" exact="viral" post="attachment. After three washes to remove unbound viruses, Ery-Est"/>
  <result pre="with ZIKV at 37 Â°C for 1 h to allow" exact="viral" post="entry, the drug was added to cells and incubated"/>
  <result pre="containing the free drugs was removed, and the pellet containing" exact="viral" post="particles was washed by 3% PEG-8000 in PBS containing"/>
  <result pre="the pellet were resuspended in DMEM and the infectivity of" exact="viral" post="particles was detected by plaque assay. 2.9. RNase Digestion"/>
  <result pre="h at 37 Â°C, followed by the inactivation of the" exact="residual" post="RNase. Then, the undigested genomic RNA inside the unbroken"/>
  <result pre="RNA inside the unbroken virus was extracted using the EasyPure" exact="Viral" post="DNA/RNA Kit (Transgen Biotech, Beijing, China) and detected using"/>
  <result pre="instructions. The primers used to detect the RNA sequences coding" exact="viral" post="E protein were as follows: F1 (5â€²-TGGAGGCTGAGATGGATGG-3â€²)/R1 (5â€²-GAACGCTGCGGTACACAAGGA-3â€²). 2.10."/>
  <result pre="bottom and detected for E protein by western blot and" exact="viral" post="genomic RNA by RT-qPCR. Anti-E mAb 4G2 (10 Âµg/mL)"/>
  <result pre="be protected if a mouse survived to 21 days post" exact="infection" post="(dpi). The viral RNA loads of sera were measured"/>
  <result pre="a mouse survived to 21 days post infection (dpi). The" exact="viral" post="RNA loads of sera were measured 2 dpi by"/>
  <result pre="Three embryos of each mouse were randomly collected to detect" exact="viral" post="RNA loads of placentas and fetal heads from those"/>
  <result pre="to the sample size. 3. Results 3.1. Ery-Est Inhibited ZIKV" exact="Infection" post="in Different Cell Types To determine the inhibitory activity"/>
  <result pre="susceptible to ZIKV and develop obvious cytopathic effects (CPE) after" exact="infection" post="[38], and the ZIKV-forming plaques were presented visually by"/>
  <result pre="assay were generally unchanged. This suggests that Ery-Est inhibits ZIKV" exact="infection" post="in a dose-dependent manner. The 50% inhibitory concentration (IC50)"/>
  <result pre="To test the inhibitory activity of Ery-Est against ZIKV in" exact="neuronal" post="cells whose damage caused by ZIKV was especially serious,"/>
  <result pre="caused by ZIKV was especially serious, which would reduce fetal" exact="brain" post="growth, U-251 MG cells were infected by ZIKV with"/>
  <result pre="and Ery treatments. It was found that Ery-Est significantly reduced" exact="infection" post="rates of U-251 MG cells with an IC50 value"/>
  <result pre="thus, could be detected by CCK8, which could evaluate ZIKV" exact="infection" post="indirectly. As a result, Ery-Est was testified to inhibit"/>
  <result pre="a result, Ery-Est was testified to inhibit ZIKV strain SZ01" exact="infection" post="with IC50 values of 3.55 Â± 0.46 and 3.97"/>
  <result pre="Taken together, these data indicate that Ery-Est notably inhibits ZIKV" exact="infection" post="in different cell types, including neuronal cells. In addition,"/>
  <result pre="Ery-Est notably inhibits ZIKV infection in different cell types, including" exact="neuronal" post="cells. In addition, to monitor the inhibitory activity of"/>
  <result pre="In addition, to monitor the inhibitory activity of Ery-Est against" exact="viral" post="growth, Ery-Est was tested to inhibit ZIKV infection in"/>
  <result pre="Ery-Est against viral growth, Ery-Est was tested to inhibit ZIKV" exact="infection" post="in a multistep growth curve. It was demonstrated that"/>
  <result pre="also shown that Ery-Est could exhibit inhibitory activity against ZIKV" exact="infection" post="even with relatively higher viral doses (Figure S2B), and"/>
  <result pre="exhibit inhibitory activity against ZIKV infection even with relatively higher" exact="viral" post="doses (Figure S2B), and viral titers were reduced by"/>
  <result pre="infection even with relatively higher viral doses (Figure S2B), and" exact="viral" post="titers were reduced by treatment of different concentrations of"/>
  <result pre="different concentrations of Ery-Est. Treatment of 5 ÂµM Ery-Est decreased" exact="viral" post="titers by approximately 80% compared with control group, indicating"/>
  <result pre="group, indicating that Ery-Est remained effective against relatively higher dose" exact="infection" post="of ZIKV. 3.2. Ery-Est Inhibited ZIKV Strains FLR and"/>
  <result pre="ZIKV Strains FLR and MR766, DENV II, and YFV 17D" exact="Infections" post="As Ery-Est was demonstrated to potently inhibit ZIKV strain"/>
  <result pre="assay. As shown in Figure 2A,B, Ery-Est significantly inhibited the" exact="infections" post="of ZIKV strains FLR and MR766 with IC50 values"/>
  <result pre="DENV and YFV. It was demonstrated that Ery-Est potently inhibited" exact="infections" post="of DENV II and YFV 17D with IC50 values"/>
  <result pre="cells, we further tested whether Ery-Est could effectively inhibit the" exact="infection" post="of ZIKV (V-ZIKV) produced in one kind of mammalian"/>
  <result pre="cells. Supplementary Figure S3 showed that Ery-Est significantly inhibited V-ZIKV" exact="infection" post="with IC50 value of about 3.66 Â± 0.11 ÂµM,"/>
  <result pre="2G,H). These results indicate that Ery-Est may effectively inhibit flavivirus" exact="infections" post="with a broad spectrum. 3.3. Ery-Est Inhibited ZIKV Infection"/>
  <result pre="flavivirus infections with a broad spectrum. 3.3. Ery-Est Inhibited ZIKV" exact="Infection" post="in the Early Stage To determine which step of"/>
  <result pre="in the Early Stage To determine which step of the" exact="viral" post="cycle was susceptible to Ery-Est inhibition, we developed the"/>
  <result pre="addition of Ery-Est to BHK21 cells at 0 h post" exact="infection" post="significantly decreased the plaque numbers caused by ZIKV, showing"/>
  <result pre="addition time from 1 h to 4 h, showed gradually" exact="lower" post="inhibitory activity but barely suppressed virus infection from 8"/>
  <result pre="4 h, showed gradually lower inhibitory activity but barely suppressed" exact="virus infection" post="from 8 h post infection. Generally, Ery-Est inhibited ZIKV"/>
  <result pre="h, showed gradually lower inhibitory activity but barely suppressed virus" exact="infection" post="from 8 h post infection. Generally, Ery-Est inhibited ZIKV"/>
  <result pre="infection from 8 h post infection. Generally, Ery-Est inhibited ZIKV" exact="infection" post="mainly in the early 2 h stage post infection,"/>
  <result pre="2 h stage post infection, indicating that Ery-Est inhibits ZIKV" exact="infection" post="in the early stage. Next, to confirm the particular"/>
  <result pre="Ery-Est against ZIKV, experiments of separate stages that go through" exact="viral" post="entry and post-entry stages were carried out as previously"/>
  <result pre="shown in Figure 3B, Ery-Est exhibited obvious inhibitory effects on" exact="viral" post="entry, but barely inhibited ZIKV infection in the viral"/>
  <result pre="obvious inhibitory effects on viral entry, but barely inhibited ZIKV" exact="infection" post="in the viral post-entry stage. The result was consistent"/>
  <result pre="on viral entry, but barely inhibited ZIKV infection in the" exact="viral" post="post-entry stage. The result was consistent with above time-of-addition"/>
  <result pre="early stage. However, Azi targeted the post-entry stage in the" exact="viral" post="life cycle, exhibiting different inhibitory mechanisms from Ery-Est. As"/>
  <result pre="viral life cycle, exhibiting different inhibitory mechanisms from Ery-Est. As" exact="viral" post="entry consists of various processes, including viral attachment and"/>
  <result pre="from Ery-Est. As viral entry consists of various processes, including" exact="viral" post="attachment and fusion, we developed separate experiments to further"/>
  <result pre="mainly obstructs ZIKV attachment, implying that Ery-Est may bind to" exact="viral" post="particles to reduce its infectivity. We, thus, further investigated"/>
  <result pre="0.41 ÂµM respectively. These data indicate that Ery-Est inhibits virus" exact="infections" post="through directly inactivating viral particles. It was reported that"/>
  <result pre="data indicate that Ery-Est inhibits virus infections through directly inactivating" exact="viral" post="particles. It was reported that some ZIKV inhibitors, such"/>
  <result pre="reported that some ZIKV inhibitors, such as Z2 and human" exact="breast" post="milk, could inactivate virus particles by destructing the integrity"/>
  <result pre="3F,G), implying the reduction of genomic RNA inside the integrated" exact="viral" post="particles. About 80% genomic RNA was digested by the"/>
  <result pre="fourth to sixth fractions (Figure 3H,I), implying the destruction of" exact="viral" post="integrity. These results indicate that Ery-Est may inhibit ZIKV"/>
  <result pre="viral integrity. These results indicate that Ery-Est may inhibit ZIKV" exact="infection" post="by destructing the viral integrity, resulting in the release"/>
  <result pre="indicate that Ery-Est may inhibit ZIKV infection by destructing the" exact="viral" post="integrity, resulting in the release of genomic RNA. 3.5."/>
  <result pre="release of genomic RNA. 3.5. Ery-Est Protected A129 Mice from" exact="Lethal" post="ZIKV Challenge As the results in vitro demonstrated that"/>
  <result pre="50 mg/kg once a day for consecutive 7 days. The" exact="viral" post="RNA loads of sera were measured 2 dpi by"/>
  <result pre="groups of Ery or vehicle treatments (Figure 5A). Meanwhile, the" exact="viral" post="load of ZIKV in placentas and fetal heads from"/>
  <result pre="fetal heads from pregnant mice with Ery-Est treatment was significantly" exact="lower" post="than that from mice with Ery or vehicle treatments"/>
  <result pre="mice with Ery or vehicle treatments (Figure 5B,C). Besides, the" exact="infection" post="rates of placentas and fetal heads were decreased by"/>
  <result pre="penetrated to the placenta and then the fetus, thus reducing" exact="infection" post="rates of placentas and fetuses, as well as blocking"/>
  <result pre="and eliminating Aedes, the main vector of ZIKV, remains the" exact="primary" post="preventive measure. The high throughput screening of already-approved drugs"/>
  <result pre="ZIKV. In our study, Ery-Est was demonstrated to inhibit ZIKV" exact="infection" post="in a dose-dependent manner in plaque assay (Figure 1B,C"/>
  <result pre="2A,B). It was also shown that Ery-Est could still suppress" exact="viral" post="growth and exhibit inhibitory activity against ZIKV infection even"/>
  <result pre="still suppress viral growth and exhibit inhibitory activity against ZIKV" exact="infection" post="even with relatively higher viral dose (Figure S2A,B), and"/>
  <result pre="exhibit inhibitory activity against ZIKV infection even with relatively higher" exact="viral" post="dose (Figure S2A,B), and treatment of 5 ÂµM Ery-Est"/>
  <result pre="dose (Figure S2A,B), and treatment of 5 ÂµM Ery-Est decreased" exact="viral" post="titers by approximately 80% (Figure S2B). It was reported"/>
  <result pre="synthesis of bacteria and is mainly used for Staphylococcus aureus" exact="infection" post="and other diverse bacillosis [45]. To the best of"/>
  <result pre="the paper (Figure 3B), probably caused by different effects on" exact="viral" post="particles and host cells due to their different structures."/>
  <result pre="who are most likely to suffer serious consequences of abortion," exact="premature birth," post="or having a baby with microcephaly [48,49,50,51]. Meanwhile, as"/>
  <result pre="consequences of abortion, premature birth, or having a baby with" exact="microcephaly" post="[48,49,50,51]. Meanwhile, as the sexual transmission of ZIKV was"/>
  <result pre="indicating it may have a good effect on decreasing fetal" exact="infection" post="risk or reducing fetal symptoms when used for infected"/>
  <result pre="co-infections by ZIKV and DENV, in epidemic areas where the" exact="viral" post="vector, Aedes aegypti, is prevalent. Moreover, it was reported"/>
  <result pre="was reported that preexisting DENV antibodies may aggravate the ZIKV" exact="infection" post="through an antibody-dependent enhancement (ADE) effect [54,55], the phenomenon"/>
  <result pre="flavivirus, may be the affordable choice for patients with simultaneous" exact="infections" post="without the risk of ADE effects. At present, many"/>
  <result pre="of ADE effects. At present, many micromolecular inhibitors that target" exact="viral" post="binding, endocytosis, and replication against ZIKV have been discovered,"/>
  <result pre="first and then destabilizes envelope proteins and lipids of the" exact="viral" post="membrane. As a consequence, the integrity of the viral"/>
  <result pre="the viral membrane. As a consequence, the integrity of the" exact="viral" post="membrane is disrupted which results in the loss of"/>
  <result pre="viral membrane is disrupted which results in the loss of" exact="viral" post="infectivity. The detailed inactivation mechanism of Ery-Est remains to"/>
  <result pre="to be further studied in the future. Ery-Est, as a" exact="viral" post="inactivator like Z2 that is a synthetic peptide derived"/>
  <result pre="envelope proteins, makes it possible to effectively inhibit ZIKV before" exact="viral" post="entry and is, therefore, beneficial to treat infectors with"/>
  <result pre="is, therefore, beneficial to treat infectors with viremia [27]. The" exact="viral" post="inactivator, on the other hand, will promptly work once"/>
  <result pre="once it contacts the virus, which may directly reduce the" exact="viral" post="load into target cells. Likewise, Ery-Est may prevent the"/>
  <result pre="further repurposed as a novel antiviral drug to treat ZIKV" exact="infection" post="in populations with high risk, particularly pregnant women. Acknowledgments"/>
  <result pre="was supported by the National Megaprojects of China for Major" exact="Infectious" post="Diseases (2018ZX10301403 to L.L.), the National Natural Science Foundation"/>
  <result pre="supported by the National Megaprojects of China for Major Infectious" exact="Diseases" post="(2018ZX10301403 to L.L.), the National Natural Science Foundation of"/>
  <result pre="rounds of infection; Inhibitory activity of Ery-Est against high dose" exact="infection" post="of ZIKV. Figure S3: Inhibition of Ery-Est against ZIKV"/>
  <result pre="Hyg.19524650952010.1016/0035-9203(52)90042-412995440 2.MacnamaraF.N.Zika virus: A report on three cases of human" exact="infection" post="during an epidemic of jaundice in NigeriaTrans. R Soc."/>
  <result pre="emerging Zika virus in the Pacific areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 4.JouannicJ.M.FriszerS.Leparc-GoffartI.GarelC.Eyrolle-GuignotD.Zika" exact="virus infection" post="in French PolynesiaLancet20163871051105210.1016/S0140-6736(16)00625-5 5.Zika Virus Outbreaks in the AmericasAvailable"/>
  <result pre="Zika virus in the Pacific areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 4.JouannicJ.M.FriszerS.Leparc-GoffartI.GarelC.Eyrolle-GuignotD.Zika virus" exact="infection" post="in French PolynesiaLancet20163871051105210.1016/S0140-6736(16)00625-5 5.Zika Virus Outbreaks in the AmericasAvailable"/>
  <result pre="and epididymis of immunodeficient miceNat. Commun.20189535010.1038/s41467-018-07782-x30559387 8.De MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic" exact="neuropathy" post="and congenital glaucoma associated with probable Zika virus infection"/>
  <result pre="of immunodeficient miceNat. Commun.20189535010.1038/s41467-018-07782-x30559387 8.De MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic neuropathy and" exact="congenital" post="glaucoma associated with probable Zika virus infection in Venezuelan"/>
  <result pre="immunodeficient miceNat. Commun.20189535010.1038/s41467-018-07782-x30559387 8.De MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic neuropathy and congenital" exact="glaucoma" post="associated with probable Zika virus infection in Venezuelan patientsJMM"/>
  <result pre="al.Corrigendum: Optic neuropathy and congenital glaucoma associated with probable Zika" exact="virus infection" post="in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections: Zika virus"/>
  <result pre="Optic neuropathy and congenital glaucoma associated with probable Zika virus" exact="infection" post="in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections: Zika virus"/>
  <result pre="virus infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections: Zika" exact="virus infection" post="could trigger Guillain-Barre syndromeNat. Rev. Neurol.20161218710.1038/nrneurol.2016.3026988905 10.CarteauxG.MaquartM.BedetA.ContouD.BrugieresP.FouratiS.Cleret de LangavantL.de"/>
  <result pre="infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections: Zika virus" exact="infection" post="could trigger Guillain-Barre syndromeNat. Rev. Neurol.20161218710.1038/nrneurol.2016.3026988905 10.CarteauxG.MaquartM.BedetA.ContouD.BrugieresP.FouratiS.Cleret de LangavantL.de"/>
  <result pre="BrouckerT.Brun-BuissonC.Leparc-GoffartI.et al.Zika Virus Associated with MeningoencephalitisN. Engl. J. Med.20163741595159610.1056/NEJMc160296426958738 11.WoodsC.G.BondJ.EnardW.Autosomal" exact="recessive" post="primary microcephaly (MCPH): A review of clinical, molecular, and"/>
  <result pre="al.Zika Virus Associated with MeningoencephalitisN. Engl. J. Med.20163741595159610.1056/NEJMc160296426958738 11.WoodsC.G.BondJ.EnardW.Autosomal recessive" exact="primary" post="microcephaly (MCPH): A review of clinical, molecular, and evolutionary"/>
  <result pre="Virus Associated with MeningoencephalitisN. Engl. J. Med.20163741595159610.1056/NEJMc160296426958738 11.WoodsC.G.BondJ.EnardW.Autosomal recessive primary" exact="microcephaly" post="(MCPH): A review of clinical, molecular, and evolutionary findingsAm."/>
  <result pre="Dis.20163ofw17510.1093/ofid/ofw17527747251 14.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus" exact="Infection" post="in Different Cell ModelsViruses2016832210.3390/v8120322 15.LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.ZhangN.N.WatanabeM.DongH.L.LiuP.et al.25-Hydroxycholesterol Protects Host against"/>
  <result pre="Different Cell ModelsViruses2016832210.3390/v8120322 15.LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.ZhangN.N.WatanabeM.DongH.L.LiuP.et al.25-Hydroxycholesterol Protects Host against Zika Virus" exact="Infection" post="and Its Associated Microcephaly in a Mouse ModelImmunity20174644645610.1016/j.immuni.2017.02.01228314593 16.RauschK.HackettB.A.WeinbrenN.L.ReederS.M.SadovskyY.HunterC.A.SchultzD.C.CoyneC.B.CherryS.Screening"/>
  <result pre="al.25-Hydroxycholesterol Protects Host against Zika Virus Infection and Its Associated" exact="Microcephaly" post="in a Mouse ModelImmunity20174644645610.1016/j.immuni.2017.02.01228314593 16.RauschK.HackettB.A.WeinbrenN.L.ReederS.M.SadovskyY.HunterC.A.SchultzD.C.CoyneC.B.CherryS.Screening Bioactives Reveals Nanchangmycin as"/>
  <result pre="against Zika Virus Infection and Its Associated Microcephaly in a" exact="Mouse" post="ModelImmunity20174644645610.1016/j.immuni.2017.02.01228314593 16.RauschK.HackettB.A.WeinbrenN.L.ReederS.M.SadovskyY.HunterC.A.SchultzD.C.CoyneC.B.CherryS.Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum"/>
  <result pre="Rep.20171880481510.1016/j.celrep.2016.12.06828099856 17.ArabiY.M.DeebA.M.Al-HameedF.MandourahY.AlmekhlafiG.A.SindiA.A.Al-OmariA.ShalhoubS.MadyA.AlraddadiB.et al.Macrolides in critically ill patients with Middle East" exact="Respiratory" post="SyndromeInt. J. Infect. Dis.20198118419010.1016/j.ijid.2019.01.04130690213 18.YokotaS.OkabayashiT.HirakawaS.TsutsumiH.HimiT.FujiiN.Clarithromycin suppresses human respiratory syncytial"/>
  <result pre="Middle East Respiratory SyndromeInt. J. Infect. Dis.20198118419010.1016/j.ijid.2019.01.04130690213 18.YokotaS.OkabayashiT.HirakawaS.TsutsumiH.HimiT.FujiiN.Clarithromycin suppresses human" exact="respiratory" post="syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production"/>
  <result pre="virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a" exact="pulmonary" post="epithelial cell lineMediat. Inflamm.2012201252856810.1155/2012/528568 19.DongS.KangS.Identification of anti-flaviviral drugs with"/>
  <result pre="infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary" exact="epithelial" post="cell lineMediat. Inflamm.2012201252856810.1155/2012/528568 19.DongS.KangS.Identification of anti-flaviviral drugs with mosquitocidal"/>
  <result pre="LulloE.AriasC.KnoppK.A.LaurieM.T.Sandoval-EspinosaC.Mancia LeonW.R.KrencikR.UllianE.M.SpatazzaJ.et al.Zika virus cell tropism in the developing human" exact="brain" post="and inhibition by azithromycinAm. Proc. Natl. Acad. Sci. USA2016113144081441310.1073/pnas.161802911327911847"/>
  <result pre="Natl. Acad. Sci. USA2016113144081441310.1073/pnas.161802911327911847 23.WuY.H.TsengC.K.LinC.K.WeiC.K.LeeJ.C.YoungK.C.ICR suckling mouse model of Zika" exact="virus infection" post="for disease modeling and drug validationPLoS Negl. Trop. Dis.20181210.1371/journal.pntd.0006848"/>
  <result pre="Acad. Sci. USA2016113144081441310.1073/pnas.161802911327911847 23.WuY.H.TsengC.K.LinC.K.WeiC.K.LeeJ.C.YoungK.C.ICR suckling mouse model of Zika virus" exact="infection" post="for disease modeling and drug validationPLoS Negl. Trop. Dis.20181210.1371/journal.pntd.0006848"/>
  <result pre="USA2016113144081441310.1073/pnas.161802911327911847 23.WuY.H.TsengC.K.LinC.K.WeiC.K.LeeJ.C.YoungK.C.ICR suckling mouse model of Zika virus infection for" exact="disease" post="modeling and drug validationPLoS Negl. Trop. Dis.20181210.1371/journal.pntd.0006848 24.DengY.Q.ZhaoH.LiX.F.ZhangN.N.LiuZ.Y.JiangT.GuD.Y.ShiL.HeJ.A.QinC.F.et al.Isolation,"/>
  <result pre="the fusion loop of E proteinPLoS ONE20116e1605910.1371/journal.pone.001605921264311 27.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.QinC.F.JiangS.LuL.et al.A peptide-based" exact="viral" post="inactivator inhibits Zika virus infection in pregnant mice and"/>
  <result pre="E proteinPLoS ONE20116e1605910.1371/journal.pone.001605921264311 27.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.QinC.F.JiangS.LuL.et al.A peptide-based viral inactivator inhibits Zika" exact="virus infection" post="in pregnant mice and fetusesNat. Commun.201781567210.1038/ncomms1567228742068 28.XieJ.LiuJ.H.LiuH.LiaoX.Z.ChenY.LinM.G.GuY.Y.LiuT.L.WangD.M.GeH.et al.Tanshinone IIA"/>
  <result pre="proteinPLoS ONE20116e1605910.1371/journal.pone.001605921264311 27.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.QinC.F.JiangS.LuL.et al.A peptide-based viral inactivator inhibits Zika virus" exact="infection" post="in pregnant mice and fetusesNat. Commun.201781567210.1038/ncomms1567228742068 28.XieJ.LiuJ.H.LiuH.LiaoX.Z.ChenY.LinM.G.GuY.Y.LiuT.L.WangD.M.GeH.et al.Tanshinone IIA"/>
  <result pre="and fetusesNat. Commun.201781567210.1038/ncomms1567228742068 28.XieJ.LiuJ.H.LiuH.LiaoX.Z.ChenY.LinM.G.GuY.Y.LiuT.L.WangD.M.GeH.et al.Tanshinone IIA combined with adriamycin inhibited" exact="malignant" post="biological behaviors of NSCLC A549 cell line in a"/>
  <result pre="al.Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of" exact="NSCLC" post="A549 cell line in a synergistic wayBMC Cancer20161689910.1186/s12885-016-2921-x27863471 29.EspanoE.NamJ.H.SongE.J.Lipophilic"/>
  <result pre="virus production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and" exact="chikungunya" post="virus infection by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based"/>
  <result pre="production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and chikungunya" exact="virus infection" post="by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based discovery of"/>
  <result pre="in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and chikungunya virus" exact="infection" post="by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based discovery of"/>
  <result pre="inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based discovery of Middle East" exact="respiratory" post="syndrome coronavirus fusion inhibitorNat. Commun.20145306710.1038/ncomms406724473083 32.ZhaoG.DuL.MaC.LiY.LiL.PoonV.K.WangL.ZhengB.J.JiangS.ZhouY.et al.A safe and"/>
  <result pre="cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based discovery of Middle East respiratory" exact="syndrome" post="coronavirus fusion inhibitorNat. Commun.20145306710.1038/ncomms406724473083 32.ZhaoG.DuL.MaC.LiY.LiL.PoonV.K.WangL.ZhengB.J.JiangS.ZhouY.et al.A safe and convenient"/>
  <result pre="pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for" exact="viral" post="entry inhibitors against the novel human coronavirus MERS-CoVVirol. J.20131026610.1186/1743-422X-10-26623978242"/>
  <result pre="of virus-host fusion via wrapping the HR2 domain prevalent in" exact="viral" post="envelopesSci. Adv.20184eaau840810.1126/sciadv.aau840830474060 34.LuL.PanC.LiY.LuH.HeW.JiangS.A bivalent recombinant protein inactivates HIV-1 by"/>
  <result pre="recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion" exact="intermediate" post="induced by CD4 D1D2 domainsRetrovirology2012910410.1186/1742-4690-9-10423217195 35.LokS.M.CostinJ.M.HrobowskiY.M.HoffmannA.R.RoweD.K.KukkaroP.WimleyW.C.IsernS.RossmannM.G.MichaelS.F.et al.Release of dengue"/>
  <result pre="virus genome induced by a peptide inhibitorPLoS ONE20127e5099510.1371/journal.pone.005099523226444 36.AliotaM.T.CaineE.A.WalkerE.C.LarkinK.E.CamachoE.OsorioJ.E.Characterization of" exact="Lethal" post="Zika Virus Infection in AG129 MicePLoS Negl. Trop. Dis.201610e000468210.1371/journal.pntd.000468227093158"/>
  <result pre="by a peptide inhibitorPLoS ONE20127e5099510.1371/journal.pone.005099523226444 36.AliotaM.T.CaineE.A.WalkerE.C.LarkinK.E.CamachoE.OsorioJ.E.Characterization of Lethal Zika Virus" exact="Infection" post="in AG129 MicePLoS Negl. Trop. Dis.201610e000468210.1371/journal.pntd.000468227093158 37.LiS.ArmstrongN.ZhaoH.HouW.LiuJ.ChenC.ZhongC.LiuC.ZhuH.XiaN.et al.Zika Virus"/>
  <result pre="Negl. Trop. Dis.201610e000468210.1371/journal.pntd.000468227093158 37.LiS.ArmstrongN.ZhaoH.HouW.LiuJ.ChenC.ZhongC.LiuC.ZhuH.XiaN.et al.Zika Virus Fatally Infects Wild Type" exact="Neonatal" post="Mice and Replicates in Central Nervous SystemViruses2018104910.3390/v10010049 38.ChanJ.F.YipC.C.TsangJ.O.TeeK.M.CaiJ.P.ChikK.K.ZhuZ.JinD.Y.ChanK.H.YuenK.Y.et al.Differential"/>
  <result pre="Virus Fatally Infects Wild Type Neonatal Mice and Replicates in" exact="Central" post="Nervous SystemViruses2018104910.3390/v10010049 38.ChanJ.F.YipC.C.TsangJ.O.TeeK.M.CaiJ.P.ChikK.K.ZhuZ.JinD.Y.ChanK.H.YuenK.Y.et al.Differential cell line susceptibility to the"/>
  <result pre="and Replicates in Central Nervous SystemViruses2018104910.3390/v10010049 38.ChanJ.F.YipC.C.TsangJ.O.TeeK.M.CaiJ.P.ChikK.K.ZhuZ.JinD.Y.ChanK.H.YuenK.Y.et al.Differential cell line" exact="susceptibility to" post="the emerging Zika virus: Implications for disease pathogenesis, non-vector-borne"/>
  <result pre="cell line susceptibility to the emerging Zika virus: Implications for" exact="disease" post="pathogenesis, non-vector-borne human transmission and animal reservoirsEmerg. Microbes Infect.20165e9310.1038/emi.2016.9927553173"/>
  <result pre="Microbes Infect.20165e9310.1038/emi.2016.9927553173 39.ConzelmannC.ZouM.GrossR.HarmsM.RockerA.RiedelC.U.MunchJ.MullerJ.A.Storage-Dependent Generation of Potent Anti-ZIKV Activity in Human" exact="Breast" post="MilkViruses20191159110.3390/v11070591 40.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ShiY.QinC.F.QiJ.GaoG.F.et al.Structures of the Zika Virus Envelope Protein"/>
  <result pre="Human Breast MilkViruses20191159110.3390/v11070591 40.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ShiY.QinC.F.QiJ.GaoG.F.et al.Structures of the Zika Virus Envelope" exact="Protein" post="and Its Complex with a Flavivirus Broadly Protective AntibodyCell"/>
  <result pre="40.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ShiY.QinC.F.QiJ.GaoG.F.et al.Structures of the Zika Virus Envelope Protein and Its" exact="Complex" post="with a Flavivirus Broadly Protective AntibodyCell Host Microbe20161969670410.1016/j.chom.2016.04.01327158114 41.ParkJ.G.Avila-PerezG.MadereF.HilimireT.A.NogalesA.AlmazanF.Martinez-SobridoL.Potent"/>
  <result pre="as determined by high-pressure liquid chromatographyAntimicrob. Agents Chemother.19883256156510.1128/AAC.32.4.5613259856 45.AltunaijiS.KukuruzovicR.CurtisN.MassieJ.Antibiotics for" exact="whooping cough" post="(pertussis)Cochrane Database Syst. Rev.2007Cd00440410.1002/14651858.CD004404.pub317636756 46.LangleyJ.M.HalperinS.A.BoucherF.D.SmithB.Azithromycin is as effective as"/>
  <result pre="the vagina in pregnancyCochrane Database Syst. Rev.2004Cd00376710.1002/14651858.CD003767.pub214974036 48.DeCockerK.Zika Virus and" exact="Pregnancy" post="ConcernsNurs. Clin. N. Am.20195428529510.1016/j.cnur.2019.02.005 49.GrazelR.Harris-HamanP.Zika Virus Infection: A Vector-Borne"/>
  <result pre="Virus Infection: A Vector-Borne Threat to Pregnant Women and InfantsAdv." exact="Neonatal" post="Care20181835035910.1097/ANC.000000000000055730239403 50.MotaV.M.R.CavalcantiL.P.G.DelfinoA.D.S.LopesT.PessoaA.L.S.RibeiroE.M.Abortion in Cases of Zika Virus Congenital InfectionRev."/>
  <result pre="and InfantsAdv. Neonatal Care20181835035910.1097/ANC.000000000000055730239403 50.MotaV.M.R.CavalcantiL.P.G.DelfinoA.D.S.LopesT.PessoaA.L.S.RibeiroE.M.Abortion in Cases of Zika Virus" exact="Congenital" post="InfectionRev. Bras. Ginecol. Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and Motor Deficits in"/>
  <result pre="of Zika Virus Congenital InfectionRev. Bras. Ginecol. Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and" exact="Motor" post="Deficits in Grown-up Mice with Congenital Zika Virus InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742"/>
  <result pre="Ginecol. Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and Motor Deficits in Grown-up Mice with" exact="Congenital" post="Zika Virus InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of"/>
  <result pre="of Zika virusPathogens201876610.3390/pathogens7030066 53.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent Zika Virus Sexual Transmission and Prolonged" exact="Viral" post="RNA Shedding in an Immunodeficient Mouse ModelCell Rep.2017181751176010.1016/j.celrep.2017.01.05628199846 54.GunawardanaS.A.ShawR.H.Cross-reactive"/>
  <result pre="Sexual Transmission and Prolonged Viral RNA Shedding in an Immunodeficient" exact="Mouse" post="ModelCell Rep.2017181751176010.1016/j.celrep.2017.01.05628199846 54.GunawardanaS.A.ShawR.H.Cross-reactive dengue virus-derived monoclonal antibodies to Zika"/>
  <result pre="Pandoraâ€™s box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531 55.LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.LiuR.WangJ.ZhangF.JinX.et al.Dengue immune sera enhance Zika" exact="virus infection" post="in human peripheral blood monocytes through Fc gamma receptorsPLoS"/>
  <result pre="box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531 55.LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.LiuR.WangJ.ZhangF.JinX.et al.Dengue immune sera enhance Zika virus" exact="infection" post="in human peripheral blood monocytes through Fc gamma receptorsPLoS"/>
  <result pre="55.LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.LiuR.WangJ.ZhangF.JinX.et al.Dengue immune sera enhance Zika virus infection in human" exact="peripheral" post="blood monocytes through Fc gamma receptorsPLoS ONE201813e020047810.1371/journal.pone.020047830044839 56.DurbinA.P.Dengue Antibody"/>
  <result pre="human peripheral blood monocytes through Fc gamma receptorsPLoS ONE201813e020047810.1371/journal.pone.020047830044839 56.DurbinA.P.Dengue" exact="Antibody" post="and Zika: Friend or Foe?Trends Immunol.20163763563610.1016/j.it.2016.08.00627599407 57.MorroneS.R.LokS.M.Structural perspectives of"/>
  <result pre="Friend or Foe?Trends Immunol.20163763563610.1016/j.it.2016.08.00627599407 57.MorroneS.R.LokS.M.Structural perspectives of antibody-dependent enhancement of" exact="infection" post="of dengue virusCurr. Opin. Virol.2019361810.1016/j.coviro.2019.02.00230844538 58.SapparapuG.FernandezE.KoseN.BinC.FoxJ.M.BombardiR.G.FremontD.H.DoranzB.J.DiamondM.S.CroweJ.E.et al.Neutralizing human antibodies"/>
  <result pre="58.SapparapuG.FernandezE.KoseN.BinC.FoxJ.M.BombardiR.G.FremontD.H.DoranzB.J.DiamondM.S.CroweJ.E.et al.Neutralizing human antibodies prevent Zika virus replication and fetal" exact="disease" post="in miceNature201654044344710.1038/nature2056427819683 Figure 1 The molecular formula of erythromycin"/>
  <result pre="crystal violet for plaque visualization and (C) the inhibitions of" exact="infection" post="were calculated. The experiment was tested in triplicate and"/>
  <result pre="Ery. The percentage of infected cells at 48 h post" exact="infection" post="was determined by flow cytometry and normalized to untreated"/>
  <result pre="SZ01 and treated by Ery-Est and Ery, then the ZIKV" exact="infection" post="was evaluated by immunofluorescence staining after 4 days. ZIKV"/>
  <result pre="p &amp;lt; 0.0001. Figure 2 Inhibition of Ery-Est against flavivirus" exact="infection" post="with a broad spectrum and its cytotoxicity. BHK21 cells"/>
  <result pre="1% crystal violet for plaque visualization and the inhibitions of" exact="infection" post="were calculated. Huh7 cells (2 Ã— 104) were infected"/>
  <result pre="**** p &amp;lt; 0.0001. Figure 3 Early stages of ZIKV" exact="infection" post="were inhibited by Ery-Est. (A) BHK21 cells (2 Ã—"/>
  <result pre="time points post infection. Plaque assay was used to detect" exact="viral infection." post="(B) The experimental scheme of viral lifecycle. In the"/>
  <result pre="used to detect viral infection. (B) The experimental scheme of" exact="viral" post="lifecycle. In the entry experiment, cells were infected with"/>
  <result pre="Ery, or DMSO at 4 Â°C for 1 h, allowing" exact="viral" post="attachment but not membrane fusion due to the low"/>
  <result pre="infected with virus at 4 Â°C for 1 h for" exact="viral" post="attachment and washed to remove the unbound viruses, then"/>
  <result pre="or DMSO was added to infected cells for 12 h." exact="Viral" post="infection of those four experiments were evaluated by plaque"/>
  <result pre="DMSO was added to infected cells for 12 h. Viral" exact="infection" post="of those four experiments were evaluated by plaque assay."/>
  <result pre="RNA in each fraction was separated and each percent of" exact="total" post="RNA genome was measured by RT-qPCR. For (A) to"/>
  <result pre="&amp;lt; 0.0001. Figure 4 Protective activity of Ery-Est against ZIKV" exact="infection" post="in lethal mouse models. Three groups of A129 mice"/>
  <result pre="with Ery-Est and Ery were used as mock controls. (A)" exact="Viral" post="RNA load in sera of A129 mice 2 dpi,"/>
  <result pre="of Ery-Est (50 mg/kg), Ery (50 mg/kg) and vehicle respectively." exact="Viral" post="RNA loads (A) in sera of pregnant mice, (B)"/>
  <result pre="placentas, and (C) in fetal heads at 1 day post" exact="infection" post="were measured by RT-qPCR. Three embryos of each pregnant"/>
 </snippets>
</snippetsTree>
